Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been assigned a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $51.11.
Several research firms have weighed in on DCPH. BidaskClub downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, May 14th. Canaccord Genuity set a $55.00 price target on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 13th. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 21st. Raymond James started coverage on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 29th. They set an “outperform” rating and a $47.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 22nd. They set an “overweight” rating and a $53.00 price objective for the company.
Deciphera Pharmaceuticals stock opened at $36.73 on Friday. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.39 billion and a P/E ratio of -12.11. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.03. equities research analysts forecast that Deciphera Pharmaceuticals will post -2.59 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC grew its position in shares of Deciphera Pharmaceuticals by 79.9% in the 2nd quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after buying an additional 655,800 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Deciphera Pharmaceuticals in the second quarter valued at $21,989,000. Orbimed Advisors LLC lifted its holdings in Deciphera Pharmaceuticals by 30.8% in the second quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock valued at $78,924,000 after acquiring an additional 472,800 shares during the period. Opaleye Management Inc. acquired a new stake in Deciphera Pharmaceuticals in the first quarter valued at $7,314,000. Finally, FMR LLC lifted its holdings in Deciphera Pharmaceuticals by 33.5% in the second quarter. FMR LLC now owns 1,182,091 shares of the company’s stock valued at $46,515,000 after acquiring an additional 296,571 shares during the period. Institutional investors and hedge funds own 53.49% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Further Reading: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.